(Q69895297)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2881320%20AND%20SRC:MED&resulttype=core&format=json

6 October 2019

title

Double blind controlled trials of cholecystokinin octapeptide in neuroleptic-refractory schizophrenia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2881320%20AND%20SRC:MED&resulttype=core&format=json

6 October 2019

1 reference

1 reference

E Peselow

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2881320%20AND%20SRC:MED&resulttype=core&format=json

6 October 2019

B Angrist

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2881320%20AND%20SRC:MED&resulttype=core&format=json

6 October 2019

A Sudilovsky

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2881320%20AND%20SRC:MED&resulttype=core&format=json

6 October 2019

J Corwin

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2881320%20AND%20SRC:MED&resulttype=core&format=json

6 October 2019

J Siekierski

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2881320%20AND%20SRC:MED&resulttype=core&format=json

6 October 2019

F Trent

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2881320%20AND%20SRC:MED&resulttype=core&format=json

6 October 2019

J Rotrosen

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2881320%20AND%20SRC:MED&resulttype=core&format=json

6 October 2019

publication date

1 January 1987

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2881320%20AND%20SRC:MED&resulttype=core&format=json

6 October 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2881320%20AND%20SRC:MED&resulttype=core&format=json

6 October 2019

volume

91

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2881320%20AND%20SRC:MED&resulttype=core&format=json

6 October 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2881320%20AND%20SRC:MED&resulttype=core&format=json

6 October 2019

page(s)

80-84

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2881320%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/bf00690931

6 October 2019

exact match

0 references

cites work

A subpopulation of mesencephalic dopamine neurons projecting to limbic areas contains a cholecystokinin-like peptide: evidence from immunohistochemistry combined with retrograde tracing

1 reference

12 December 2020

Clinical study on the psychotropic effects of caerulein--an open clinical trial in chronic schizophrenic patients

1 reference

12 December 2020

Peptide-monoamine coexistence: Studies of the actions of cholecystokinin-like peptide on the electrical activity of midbrain dopamine neurons

1 reference

12 December 2020

Modulation of [3H]-dopamine binding by cholecystokinin octapeptide (CCK-8)

1 reference

12 December 2020

Intermittent chemotherapy for chronic psychiatric inpatients

1 reference

12 December 2020

Cholecystokinin receptor binding in brain and pancreas: regulation of pancreatic binding by cyclic and acyclic guanine nucleotides

1 reference

12 December 2020

Withdrawal of perphenazine in chronic schizophrenia

1 reference

12 December 2020

Suppressive action of cholecystokinin octapeptide on the behavioral effects of L-DOPA in the rat

1 reference

12 December 2020

Cholecystokinin-mediated synaptic function and the treatment of neuropsychiatric disease

1 reference

12 December 2020

Antipsychotic effects of ceruletide (caerulein) on chronic schizophrenia

1 reference

12 December 2020

A rating scale for emotional blunting

1 reference

12 December 2020

No evidence of antipsychotic effect of caerulein in schizophrenic patients free of neuroleptics: a double-blind cross-over study

1 reference

12 December 2020

Ceruletide: A New Drug for the Treatment of Schizophrenic Patients?

1 reference

12 December 2020

Modulation by cholecystokinins of3H-spiroperidol binding in rat striatum: evidence for increased affinity and reduction in the number of binding sites

1 reference

12 December 2020

Central depressant effects of caerulein and cholecystokinin octapeptide (CCK-8) differ from those of diazepam and haloperidol

1 reference

12 December 2020

Influence of cholecystokinin octapeptide sulfate ester on brain monoamine metabolism in rats

1 reference

12 December 2020

Influence of cholecystokinin on central monoaminergic pathways

1 reference

12 December 2020

Cholecystokinin Receptors in the Brain: Characterization and Distribution

1 reference

12 December 2020

Cholecystokinin-octapeptide effects on conditioned-avoidance behavior, stereotypy and catalepsy.

1 reference

12 December 2020

The Effects of Ceruletide in Schizophrenia

1 reference

12 December 2020

Cholecystokinin peptides produce marked reduction of dopamine turnover in discrete areas in the rat brain following intraventricular injection

1 reference

12 December 2020

Cholecystokinin-like peptides potentiate apomorphine-induced inhibition of dopamine neurons

1 reference

12 December 2020

Ceruletide for schizophrenia: a double-blind study

1 reference

12 December 2020

A high-dose, double-blind study of ceruletide in the treatment of schizophrenia

1 reference

12 December 2020